Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Public ClinicalTrials.gov record NCT03108495. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Prospective, multicenter, multiple cohort, open label, interventional study evaluating adoptive cell therapy (ACT) with autologous tumor infiltrating lymphocytes (TIL) infusion (LN-145), with or without pembrolizumab, followed by IL-2 after a non-myeloablative lymphodepletion (NMA-LD) preparative regimen for the treatment of participants with recurrent, metastatic, or persistent cervical carcinoma.
Study identification
- NCT ID
- NCT03108495
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 210 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 22, 2017 (Actual)
- Primary completion
- Aug 22, 2025 (Actual)
- Completion
- Aug 22, 2025 (Actual)
- Last update posted
- Sep 25, 2026
2017 – 2025
United States locations
- U.S. sites
- 24
- U.S. states
- 19
- U.S. cities
- 23
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| St. Joseph's Hospital and Medical Center Center For Women's Health | Phoenix | Arizona | 85013 | — |
| University of Southern California | Los Angeles | California | 90033 | — |
| University of California San Diego | San Diego | California | 92093 | — |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | — |
| University of Florida Health Cancer Center | Orlando | Florida | 32806 | — |
| University of South Florida H. Lee Moffitt Cancer Center and Research Institute | Tampa | Florida | 33612 | — |
| Augusta University | Augusta | Georgia | 30912-0003 | — |
| University of Chicago | Chicago | Illinois | 60637 | — |
| James Graham Brown Cancer Center | Louisville | Kentucky | 40202 | — |
| LSU Health Sciences Center | New Orleans | Louisiana | 70112 | — |
| The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21287-0013 | — |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Rutgers University | Newark | New Jersey | 07103 | — |
| Roswell Park Cancer Institute | Buffalo | New York | 14263 | — |
| Cleveland Clinic | Cleveland | Ohio | 44195 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma | 73104 | — |
| Allegheny Health | Pittsburgh | Pennsylvania | 15224 | — |
| UPMC Cancer Center | Pittsburgh | Pennsylvania | 15232 | — |
| Avera Medical Group Oncology | Sioux Falls | South Dakota | 57105 | — |
| MD Anderson Cancer Center | Houston | Texas | 77030 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53225 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 19 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03108495, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 25, 2026 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03108495 live on ClinicalTrials.gov.